The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions. This award leverages the University's expertise to investigate approaches that could help combat ovarian cancer treatment resistance and improve patient outcomes, advancing the program's goals of developing medical solutions for service members and the public.
Generated 2/20/24, 2:28 PM